(UroToday.com) The immunotherapy and beyond thematic session at EAU virtual 2020 highlighted several presentations discussing immunotherapy combinations for intermediate-poor risk metastatic renal cell carcinoma (mRCC). Manuela Schmidinger, MD, discussed the aspect of Immuno-Oncology (IO) IO-IO combination therapy for these patients. In the first-line treatment of mRCC for patients with intermediate-poor risk disease, the combination of nivolumab plus ipilimumab showed a PFS benefit versus sunitinib (HR 0.76, 95% CI 0.62-0.91), as did pembrolizumab plus axitinib (HR 0.69, 95% CI 0.56-0.84).1-2 Additionally, both of these regimens have demonstrated an OS advantage to sunitinib: nivolumab plus ipilimumab HR 0.66, 95% CI 0.55-0.80; pembrolizumab plus axitinib HR 0.63, 95% CI 0.50-0.81: